Evidence map›Paper›PMID 34822912›Full record

ArticleJournal of virological methods2022

Surveillance of SARS-CoV-2 variants of concern by identification of single nucleotide polymorphisms in the spike protein by a multiplex real-time PCR.

Laksiri Gomes, Chandima Jeewandara, Tibutius Pramanayagam Jayadas, Osanda Dissanayake, Michael Harvie, Dinuka Guruge, Vigeetha Withanage, Pasyodun Koralage Buddhika Mahesh, Wajira Rajapakse, Rajanthi Ramachandran and 13 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Laksiri GomesAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Chandima JeewandaraAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Tibutius Pramanayagam JayadasAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Osanda DissanayakeAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Michael HarvieAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Dinuka GurugeColombo Municipal Council, Colombo, Sri Lanka.
Vigeetha WithanageMinistry of Health Sri Lanka, Sri Lanka.
Pasyodun Koralage Buddhika MaheshMinistry of Health Sri Lanka, Sri Lanka.
Wajira RajapakseMinistry of Health Sri Lanka, Sri Lanka.
Rajanthi RamachandranMinistry of Health Sri Lanka, Sri Lanka.
Venoden DharmarajanMinistry of Health Sri Lanka, Sri Lanka.
Indika PathirajaMinistry of Health Sri Lanka, Sri Lanka.
Anusha SanjeewaniMinistry of Health Sri Lanka, Sri Lanka.
Priyantha BandaraMinistry of Health Sri Lanka, Sri Lanka.
Geetha NanayakkaraMinistry of Health Sri Lanka, Sri Lanka.
Vaithehi Rajeevan FrancisFaculty of Health Care Sciences, Eastern University of Sri Lanka, Sri Lanka.
Ananda KithsiriMinistry of Health Sri Lanka, Sri Lanka.
Dilini Anushika EdirisingheMinistry of Health Sri Lanka, Sri Lanka.
Kaushalya De SilvaMinistry of Health Sri Lanka, Sri Lanka.
Ruwan WijayamuniColombo Municipal Council, Colombo, Sri Lanka.
Graham S OggMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Jesse WaggonerEmory University, Department of Medicine, Atlanta, GA, USA.
Gathsaurie Neelika MalavigeAllergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. Electronic address: gathsaurie.malavige@ndm.ox.ac.uk.
Ministry of Health, Nutrition and Indigenous Medicine · LKUniversity of Sri Jayewardenepura · LKUniversity of Colombo · LKEmory University · USMRC Human Immunology Unit · GBSouth Eastern University of Sri Lanka · LKUniversity of Oxford · GB

Funding

American Asian Centers for Arbovirus Research and Enhanced Surveillance (A2CARES)U01AI151788 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Josefina Coloma, Eva Harris · 2020 to 2026
$9.6M
Targeting Mosquito FREP1 Protein for Malaria ControlR21AI115178 · NIAID · UNIVERSITY OF OKLAHOMA · PI LI, JUN · 2015 to 2016
$421k
Medical Research Council MC_UU_00008/5NIAID NIH HHS R21 AI115178NIAID NIH HHS U01 AI151788
6 · The paper itself

Abstract

backgroundAlthough active surveillance SARS-CoV-2 variants of concern (VOCs) is required for proper outbreak control measures, many lower income countries find it challenging to detect VOCs by carrying genomic sequencing alone, due to limited resources.

methodsVOCs can also be identified by the unique mutations in the spike protein by real-time PCR that detect these single nucleotide polymorphisms (SNPs). We used a multiplex, real-time PCR assay for detection of these SNPs for identification of the prevalence of different SARS-CoV-2 VOCs in 16/26 districts in Sri Lanka.

resultsOf the 664/934 that were subjected to the multiplex qRT-PCR, 638 (96.1 %) detected L452R and K417 in the channels and were identified as the delta variant. 25 samples (3.9 %) detected N501Y, with K417 were considered as the alpha variant. Of 10/16 districts in Sri Lanka, the delta variant was the only VOC detected.

conclusionsThis multiplex real-time qRT-PCR which identifies certain SNPs specific to the VOCs appears to be a fast, cheaper and less technically demanding method to generate data regarding the spread of different SARS-CoV-2 variants, and is a suitable method for lower income countries, to supplement the data generated by genomic sequencing.

Indexed as

COVID-19SARS-CoV-2HumansMutationPolymorphism, Single NucleotideReal-Time Polymerase Chain ReactionSpike Glycoprotein, CoronavirusSpike Glycoprotein, CoronavirusMultiplex PCRMutationsSARS-CoV-2SequencingSingle nucleotide polymorphismsVariants of concern

Identifiers

PMID34822912
PMCPMC8607739
OpenAlexW3216252335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.